Chroma Medicine Stock
HealthTechLooking to sell Chroma Medicine stock or options?
Chroma Medicine is advancing genomic medicines aimed at transforming the treatment of genetically influenced diseases. The company's innovative approach leverages epigenetics, the natural mechanism for regulating genes, by employing programmable epigenetic editors. These editors specifically target genes and manage chromatin structure by pairing a DNA binding domain with epigenetic effector domains. This enables healthcare professionals to utilize a new class of therapeutics, achieving unprecedented precision in controlling gene expression.
DCVC Bio, Wellington Management, ARCH Venture Partners, Cormorant Asset Management, Atlas Venture, Sofinnova Partners, GV, Casdin Capital, Janus Capital Management, Janus Henderson Investors, Newpath Partners, Sixth Street Partners, Alexandria Real Estate Equities, Osage University Partners, Mubadala Capital, T. Rowe Price Group, Omega Funds.